Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance

JQ Wang, Y Yang, CY Cai, QX Teng, Q Cui, J Lin… - Drug Resistance …, 2021 - Elsevier
ATP-binding cassette (ABC) transporters mediate the ATP-driven translocation of structurally
and mechanistically distinct substrates against steep concentration gradients. Among the …

ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates

JQ Wang, ZX Wu, Y Yang, QX Teng… - Journal of Evidence …, 2021 - Wiley Online Library
The ATP‐binding cassette (ABC) transporter superfamily is one of the largest membrane
protein families existing in wide spectrum of organisms from prokaryotes to human. ABC …

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

J Gu, W Huang, X Wang, J Zhang, T Tao, Y Zheng… - Molecular Cancer, 2022 - Springer
Background Although gemcitabine has been considered as the first-line drug for advanced
pancreatic cancer (PC), development of resistance to gemcitabine severely limits the …

Inhibitors of human ABCG2: from technical background to recent updates with clinical implications

Y Toyoda, T Takada, H Suzuki - Frontiers in pharmacology, 2019 - frontiersin.org
The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance
protein, BCRP) has been suggested to be involved in clinical multidrug resistance (MDR) in …

[HTML][HTML] Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy

XJ Pang, XJ Liu, Y Liu, WB Liu, YR Li, GX Yu, XY Tian… - Molecules, 2021 - mdpi.com
FAK is a nonreceptor intracellular tyrosine kinase which plays an important biological
function. Many studies have found that FAK is overexpressed in many human cancer cell …

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

M Yang, H **ang, G Luo - Biochemical Pharmacology, 2024 - Elsevier
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, plays an essential role in
regulating cell proliferation, migration and invasion through both kinase-dependent …

[HTML][HTML] Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

X Wu, J Wang, Q Liang, R Tong, J Huang… - Biomedicine & …, 2022 - Elsevier
Focal adhesion kinase (FAK, also known as PTK2) is a tyrosine kinase that regulates
integrin and growth factor signaling pathways and is involved in the migration, proliferation …

Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK)

Y Lu, H Sun - Journal of Medicinal Chemistry, 2020 - ACS Publications
Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an
essential role in cancer cell adhesion, survival, proliferation, and migration through both its …

IGF-1/IGF-1R/FAK/YAP transduction signaling prompts growth effects in triple-negative breast cancer (TNBC) cells

DC Rigiracciolo, N Nohata, R Lappano, F Cirillo… - Cells, 2020 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive breast tumor subtype that currently
lacks targeted treatment options. The role played by the insulin-like growth factor-1 (IGF-1) …

FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials

A Mohanty, RR Pharaon, A Nam, S Salgia… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Focal adhesion kinase (FAK) is a promising target for the treatment of solid
tumors because its expression has been linked to tumor progression, invasion, and drug …